CXCL8 and hepatocellular carcinoma: We further compared the clinical outcome of the patients co-expressing NTS and IL-8 with the others, and found 60%(6/10) of HCC patients bearing NTS+IL-8+ tumors died after the surgery, which is about 2.5 folds of the incidence risk of 24.07%(13/54) in the other patients (P = 0.022).